Prometic Life Scienc (PFSCF) 1.1730 $PFSCF
ProMetic Secures $20 Million Follow-on Investment from Thomvest Seed Capital Inc.
Marketwire - Fri Aug 01, 7:18AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation"

announced today that it has secured a follow-on investment from Thomvest Seed Capital Inc. ("Thomvest"

, the Toronto-based investment vehicle of Peter J. Thomson, consisting of a $20 million Loan. As partial consideration for the Loan, ProMetic has granted Thomvest 16,723,807 warrants with an exercise price of $1.87 per common share, a premium of 52% to yesterday's closing share price.
ProMetic Enters Into New Product Program With an Existing Multinational Client
Marketwire - Thu Jul 24, 7:40AM CDT
July 24, 2014 - ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation"

announced today the signing of an agreement (the "Agreement"

by ProMetic's UK subsidiary, ProMetic Biosciences Ltd ("PBL"

, with one of its existing multinational clients, a global leader in the biotherapeutics industry.
ProMetic to Commercially Launch Fibrinogen in the Fourth Quarter of 2014
Marketwire - Thu Jul 10, 7:09AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation"

announced today that it will launch fibrinogen for commercial sales during the fourth quarter of 2014 after its successful scale-up at its Laval based plasma purification facility, ProMetic BioProduction Inc. ("PBP"

. This follows the previously disclosed proteins already scheduled for production at PBP, namely plasminogen, IVIG and Alpha-1 Antitrypsin.
ProMetic Successfully Completes its PBI-4050 Phase I Clinical Trial
Marketwire - Wed Jun 18, 5:01AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation"

reported today that it has successfully completed its PBI-4050 Phase I clinical trial in 40 healthy volunteers. ProMetic's PBI-4050 was found to be safe and very well tolerated without any serious adverse events reported in any of the 5 cohorts tested.
ProMetic Receives a $5.6 Million Purchase Order from Octapharma
Marketwire - Thu Jun 05, 7:03AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation"

announced today that it has received a $5.6 million purchase order under its ongoing supply agreement with Octapharma, a leading, Swiss, independent, global plasma fractionation company that specializes in human proteins. This order should be delivered during the remainder of 2014.
ProMetic Reports Successful Pre-IND Meeting with the FDA
Marketwire - Wed Apr 02, 6:02AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation"

announced today that it had a successful Pre-Investigational New Drug ("Pre-IND) meeting with the US Food and Drug Administration ("FDA"

for a plasma-derived biopharmaceutical currently under development under the NantPro, LLC joint venture.
ProMetic Reports its 2013 Fourth Quarter and Financial Year End Results and Business Highlights
Marketwire Canada - Wed Mar 26, 4:11PM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX

FSCF) ("ProMetic" or the "Corporation"

today reported revenues of $5.1 million and $20.6 million for the quarter and year ended December 31, 2013 respectively. This compares to revenues of $8.3 million and $23.3 million for the quarter and year ended December 31, 2012 respectively.
ProMetic to Report its Fourth Quarter and Year End 2013 Financial Results and Hold Conference Call/Webcast
Marketwire - Fri Mar 21, 11:55AM CDT
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF) ("ProMetic" or the "Corporation"

today announced that it will report its financial results for the fourth quarter and fiscal year ended December 31, 2013 on Wednesday March 26, 2014 after market trading hours.
ProMetic Receives $3.2 Million Via Loan Repayment
Marketwire - Tue Mar 11, 5:31AM CDT
ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("ProMetic" or the "Corporation"

announced today that it has received approximately $3.2 million via the repayment of the amended and restated loan entered into in March, 2010 by ProMetic and InvHealth Holding Inc. ("Invhealth"

, a corporation wholly-owned and controlled by Mr. Pierre Laurin, President and Chief Executing Officer of ProMetic (the "Loan"

.
Avivagen Announces Nomination of New Director Mr. G.F. Kym Anthony Standing for Election
ACCESSWIRE - Fri Feb 28, 7:02AM CST
OTTAWA, ONTARIO / February 28, 2014 / ACCESSWIRE / Avivagen Inc. (TSXV:VIV), a wellness company developing and delivering products that support and enhance the health and quality of life for animals and the people who care for them, announces the nomination of a new Director, Mr. G.F. Kym Anthony, and the retirement of its current Chairman, Mr. Jacques Brault.
ProMetic Enters Into $1.6 Million Development Agreement With New Client
Marketwire - Thu Feb 06, 12:25PM CST
ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation"

announced today that its UK based subsidiary, ProMetic BioSciences Ltd. ("PBL"

, has entered into a new agreement with a leading vaccines company, for the development of an affinity adsorbent and associated purification process for the production of a novel vaccine product.